Published on 10 Nov 2022 on Zacks via Yahoo Finance
Homology Medicines (FIXX) Reports Q3 Loss, Misses Revenue Estimates
Homology Medicines (FIXX) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.47. This compares to loss of $0.54 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of -25.53%. A quarter ago, it was expected that this gene editing company would post a loss of $0.57 per share when it actually produced a loss of $0.51, delivering a surprise of 10.53%.
Over the last four quarters, the company has surpassed consensus EPS estimates two times.